These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 19826947)

  • 1. IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo.
    Cha E; Graham L; Manjili MH; Bear HD
    Breast Cancer Res Treat; 2010 Jul; 122(2):359-69. PubMed ID: 19826947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2.
    Le HK; Graham L; Miller CH; Kmieciak M; Manjili MH; Bear HD
    Cancer Immunol Immunother; 2009 Oct; 58(10):1565-76. PubMed ID: 19198835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expansion of T Cells with Interleukin-21 for Adoptive Immunotherapy of Murine Mammary Carcinoma.
    Zoon CK; Wan W; Graham L; Bear HD
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
    Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
    Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model.
    Parviz M; Chin CS; Graham LJ; Miller C; Lee C; George K; Bear HD
    Cancer Immunol Immunother; 2003 Dec; 52(12):739-50. PubMed ID: 12827306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bryostatin/ionomycin-activated T cells mediate regression of established tumors.
    Chin CS; Graham LJ; Hamad GG; George KR; Bear HD
    J Surg Res; 2001 Jun; 98(2):108-15. PubMed ID: 11397126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma.
    Miller CH; Graham L; Bear HD
    BMC Immunol; 2010 Nov; 11():54. PubMed ID: 21050466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex vivo expansion of tumor-reactive T cells by means of bryostatin 1/ionomycin and the common gamma chain cytokines formulation.
    Kmieciak M; Toor A; Graham L; Bear HD; Manjili MH
    J Vis Exp; 2011 Jan; (47):. PubMed ID: 21304453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma.
    Huarte E; Fisher J; Turk MJ; Mellinger D; Foster C; Wolf B; Meehan KR; Fadul CE; Ernstoff MS
    Cancer Lett; 2009 Nov; 285(1):80-8. PubMed ID: 19501956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-15/IL-15Rα Heterodimeric Complex as Cancer Immunotherapy in Murine Breast Cancer Models.
    Guo S; Smeltz RB; Nanajian A; Heller R
    Front Immunol; 2020; 11():614667. PubMed ID: 33628206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
    Gold JE; Zachary DT; Osband ME
    Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice.
    Le HK; Graham L; Cha E; Morales JK; Manjili MH; Bear HD
    Int Immunopharmacol; 2009 Jul; 9(7-8):900-9. PubMed ID: 19336265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. II. Cytokine production and in vivo efficacy of glioma-sensitized lymphocytes.
    Rice CD; Baldwin NG; Biron RT; Bear HD; Merchant RE
    J Neurooncol; 1997 Mar; 32(1):29-38. PubMed ID: 9049860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Near-infrared imaging of adoptive immune cell therapy in breast cancer model using cell membrane labeling.
    Youniss FM; Sundaresan G; Graham LJ; Wang L; Berry CR; Dewkar GK; Jose P; Bear HD; Zweit J
    PLoS One; 2014; 9(10):e109162. PubMed ID: 25334026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. I. Characterization and in vivo anti-tumor activity of glioma-sensitized lymphocytes.
    Baldwin NG; Rice CD; Tuttle TM; Bear HD; Hirsch JI; Merchant RE
    J Neurooncol; 1997 Mar; 32(1):19-28. PubMed ID: 9049859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.
    Tuttle TM; Inge TH; Bethke KP; McCrady CW; Pettit GR; Bear HD
    Cancer Res; 1992 Feb; 52(3):548-53. PubMed ID: 1732041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitizing T-lymphocytes for adoptive immunotherapy by vaccination with wild-type or cytokine gene-transduced melanoma.
    Lipshy KA; Kostuchenko PJ; Hamad GG; Bland CE; Barrett SK; Bear HD
    Ann Surg Oncol; 1997 Jun; 4(4):334-41. PubMed ID: 9181234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive transfer of bryostatin-activated tumor-sensitized lymphocytes prevents or destroys tumor metastases without expansion in vitro.
    Fleming MD; Bear HD; Lipshy K; Kostuchenko PJ; Portocarero D; McFadden AW; Barrett SK
    J Immunother Emphasis Tumor Immunol; 1995 Oct; 18(3):147-55. PubMed ID: 8770770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion.
    Wang LX; Chen BG; Plautz GE
    J Immunol; 2002 Sep; 169(6):3314-20. PubMed ID: 12218152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.